All Essays

FDA warns consumers that the agency has not evaluated most CBD products and cannot say they are safe.

A new policy statement from the federal government contradicts established law on whether patent holders can seek injunctions.

After a 2018 Supreme Court case, the laboratories of democracy are busy experimenting with sports betting.

The purchasing age for cigarettes raises from 18 to 21, the FDA announces restrictions on flavored vaping products, and more…

The judicial system may need to adapt to allow climate change cases to be heard in court.

Unlike new drugs and devices, combination products may fall through the regulatory cracks.

The Regulatory Review revisits its series published over the past year.

International response to Christchurch attack shows the complexity of restricting online extremist content.

The Regulatory Review highlights the top essays written by our contributors in 2019.

Advancing technology requires regulators to act quickly to develop standards and defenses against cyberattacks.

Recent outbreaks of vaccine-preventable diseases fuel debate about vaccine policy.

The Regulatory Review highlights the top regulatory news and scholarship of 2019, as selected by our staff.